Starch Medical Launches New, Bioinert Surgical Hemostats
Starch Medical Inc. has announced the CE approval of its PerClot(TM) Polysaccharide Hemostatic System (PHS) and the StarFoam(TM) Absorbable Polysaccharide Hemostat. Introduction of PerClot(TM) PHS will commence this month in the European Union and other select international markets. The StarFoam(TM) Absorbable Polysaccharide Hemostat will launch during the 2nd quarter, 2009. PerClot(TM) PHS is an absorbable, surgical hemostat composed of Absorbable Modified Polymers (AMP(TM)). AMP(TM) technology incorporates sophisticated, plant-based polymer modification processes that yield biocompatible, polysaccharide particles. There is no thrombin, collagen, or other human or animal components in AMP(TM) particles.
-
Atrium Medical receives FDA nod for two new Omega 3 surgical mesh products
FDA Approves PEAK Surgical to market its Surgery System
Dune Medical launches a clinical trial of MarginProbeâ„¢ system
Wright Medical Group Launches of the XPANSION(R) Micrografting System on Commercial Level
